Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Takayasu's Arteriitis | Research

Altered glycosylation profiles of serum IgG in Takayasu arteritis

Authors: Lingyu Liu, Jing Li, Yunjiao Yang, Chaojun Hu, Xinping Tian

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Takayasu arteritis (TAK) is an autoimmune inflammatory disorder with an undefined etiology. This study aimed to characterize the glycosylation profiles of serum immunoglobulin G (IgG) in patients with TAK.

Methods

Lectin microarrays containing 56 types of lectins were used to detect the glycan levels of serum IgG in 164 patients with TAK, 128 patients with atherosclerosis used as disease controls (DCs), and 100 healthy controls (HCs). Differentially altered glycosylation patterns between TAK and control groups as well as between TAK subgroups were identified and further validated by lectin blot. The classification performance of the TAK-specific glycosylation change was measured by receiver-operating characteristic (ROC) curve analysis.

Results

Lectin microarray analysis revealed significantly increased N-Acetylgalactosamine (GalNAc) levels in the TAK group compared to the DC and HC groups (all p < 0.01). For TAK subgroups, significantly decreased mannosylation was observed in patients with active TAK compared to patients with inactive disease (p < 0.01). These differences were validated by lectin blot. In addition, GalNAc levels exhibited a considerable potential for discriminating patients with TAK from patients with atherosclerosis, with an area under the curve of 0.749 (p < 0.001), a sensitivity of 71.7%, and a specificity of 73.8%.

Conclusions

Serum IgG in patients with TAK displayed disease-specific glycosylation alterations. Aberrant GalNAc glycosylation showed substantial value as a diagnostic biomarker. The potential proinflammatory properties of the abnormal glycans may provide new insights into the role of humoral immunity in the pathogenesis of TAK.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rutter M, Bowley J, Lanyon PC, et al. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021;60(11):4982–90.CrossRef Rutter M, Bowley J, Lanyon PC, et al. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021;60(11):4982–90.CrossRef
2.
go back to reference Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349(2):160–9.CrossRef Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349(2):160–9.CrossRef
3.
go back to reference Berti A, Moura MC, Sechi E, et al. Beyond giant cell arteritis and Takayasu’s arteritis: secondary large vessel vasculitis and vasculitis mimickers. Curr Rheumatol Rep. 2020;22(12):88.CrossRef Berti A, Moura MC, Sechi E, et al. Beyond giant cell arteritis and Takayasu’s arteritis: secondary large vessel vasculitis and vasculitis mimickers. Curr Rheumatol Rep. 2020;22(12):88.CrossRef
4.
go back to reference Watanabe R, Berry GJ, Liang DH, et al. Cellular signaling pathways in medium and large vessel vasculitis. Front Immunol. 2020;11: 587089.CrossRef Watanabe R, Berry GJ, Liang DH, et al. Cellular signaling pathways in medium and large vessel vasculitis. Front Immunol. 2020;11: 587089.CrossRef
5.
go back to reference Gupta S. Surgical and immunological aspects of Takayasu’s disease. Ann R Coll Surg Engl. 1981;63(5):325–32. Gupta S. Surgical and immunological aspects of Takayasu’s disease. Ann R Coll Surg Engl. 1981;63(5):325–32.
6.
go back to reference Wang H, Ma J, Wu Q, et al. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg. 2011;53(1):174–80.CrossRef Wang H, Ma J, Wu Q, et al. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg. 2011;53(1):174–80.CrossRef
7.
go back to reference Schjoldager KT, Narimatsu Y, Joshi HJ, et al. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–49.CrossRef Schjoldager KT, Narimatsu Y, Joshi HJ, et al. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–49.CrossRef
8.
go back to reference Goulabchand R, Vincent T, Batteux F, et al. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev. 2014;13(7):742–50.CrossRef Goulabchand R, Vincent T, Batteux F, et al. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev. 2014;13(7):742–50.CrossRef
9.
go back to reference van de Geijn FE, Wuhrer M, Selman MH, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11(6):R193.CrossRef van de Geijn FE, Wuhrer M, Selman MH, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11(6):R193.CrossRef
10.
go back to reference Vučković F, Krištić J, Gudelj I, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015;67(11):2978–89.CrossRef Vučković F, Krištić J, Gudelj I, et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015;67(11):2978–89.CrossRef
11.
go back to reference Youinou P, Pennec YL, Casburn-Budd R, et al. Galactose terminating oligosaccharides of IgG in patients with primary Sjögren’s syndrome. J Autoimmun. 1992;5(3):393–400.CrossRef Youinou P, Pennec YL, Casburn-Budd R, et al. Galactose terminating oligosaccharides of IgG in patients with primary Sjögren’s syndrome. J Autoimmun. 1992;5(3):393–400.CrossRef
12.
go back to reference Cvetko A, Kifer D, Gornik O, et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines. 2020;8(10):410.CrossRef Cvetko A, Kifer D, Gornik O, et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines. 2020;8(10):410.CrossRef
13.
go back to reference Miyoshi E, Shinzaki S, Fujii H, et al. Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease. Proteomics Clin Appl. 2016;10(4):384–90.CrossRef Miyoshi E, Shinzaki S, Fujii H, et al. Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease. Proteomics Clin Appl. 2016;10(4):384–90.CrossRef
14.
go back to reference Selman MH, Niks EH, Titulaer MJ, et al. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res. 2011;10(1):143–52.CrossRef Selman MH, Niks EH, Titulaer MJ, et al. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res. 2011;10(1):143–52.CrossRef
15.
go back to reference Hirabayashi J, Yamada M, Kuno A, et al. Lectin microarrays: concept, principle and applications. Chem Soc Rev. 2013;42(10):4443–58.CrossRef Hirabayashi J, Yamada M, Kuno A, et al. Lectin microarrays: concept, principle and applications. Chem Soc Rev. 2013;42(10):4443–58.CrossRef
16.
go back to reference Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.CrossRef Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.CrossRef
17.
go back to reference Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.CrossRef Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.CrossRef
18.
go back to reference Cimminiello C. PAD Epidemiology and pathophysiology. Thromb Res. 2002;106(6):V295-301.CrossRef Cimminiello C. PAD Epidemiology and pathophysiology. Thromb Res. 2002;106(6):V295-301.CrossRef
19.
go back to reference Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.CrossRef Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.CrossRef
20.
go back to reference Silver JD, Ritchie ME, Smyth GK. Microarray background correction: maximum likelihood estimation for the normal-exponential convolution. Biostatistics. 2009;10(2):352–63.CrossRef Silver JD, Ritchie ME, Smyth GK. Microarray background correction: maximum likelihood estimation for the normal-exponential convolution. Biostatistics. 2009;10(2):352–63.CrossRef
21.
go back to reference Hu C, Zhang P, Li L, et al. Assessing serum IgG4 glycosylation profiles of IgG4-related disease using lectin microarray. Clin Exp Rheumatol. 2021;39(2):393–402.CrossRef Hu C, Zhang P, Li L, et al. Assessing serum IgG4 glycosylation profiles of IgG4-related disease using lectin microarray. Clin Exp Rheumatol. 2021;39(2):393–402.CrossRef
22.
go back to reference Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017;38(5):358–72.CrossRef Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017;38(5):358–72.CrossRef
23.
go back to reference Prozeller D, Rosenauer C, Morsbach S, et al. Immunoglobulins on the surface of differently charged polymer nanoparticles. Biointerphases. 2020;15(3): 031009.CrossRef Prozeller D, Rosenauer C, Morsbach S, et al. Immunoglobulins on the surface of differently charged polymer nanoparticles. Biointerphases. 2020;15(3): 031009.CrossRef
24.
go back to reference Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000;8(2):141–8.CrossRef Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000;8(2):141–8.CrossRef
25.
go back to reference Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71(1):75–9.CrossRef Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71(1):75–9.CrossRef
26.
go back to reference Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun. 2020;11(1):1253.CrossRef Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun. 2020;11(1):1253.CrossRef
27.
go back to reference Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.CrossRef Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.CrossRef
28.
go back to reference Quast I, Peschke B, Lünemann JD. Regulation of antibody effector functions through IgG Fc N-glycosylation. Cell Mol Life Sci. 2017;74(5):837–47.CrossRef Quast I, Peschke B, Lünemann JD. Regulation of antibody effector functions through IgG Fc N-glycosylation. Cell Mol Life Sci. 2017;74(5):837–47.CrossRef
29.
go back to reference Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34.CrossRef Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34.CrossRef
30.
go back to reference Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1(3):237–43.CrossRef Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1(3):237–43.CrossRef
31.
go back to reference Lood C, Allhorn M, Lood R, et al. IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? Arthritis Rheum. 2012;64(8):2698–706.CrossRef Lood C, Allhorn M, Lood R, et al. IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? Arthritis Rheum. 2012;64(8):2698–706.CrossRef
32.
go back to reference Albert H, Collin M, Dudziak D, et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008;105(39):15005–9.CrossRef Albert H, Collin M, Dudziak D, et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008;105(39):15005–9.CrossRef
33.
go back to reference Bakchoul T, Walek K, Krautwurst A, et al. Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenia. Thromb Haemost. 2013;110(6):1259–66.CrossRef Bakchoul T, Walek K, Krautwurst A, et al. Glycosylation of autoantibodies: insights into the mechanisms of immune thrombocytopenia. Thromb Haemost. 2013;110(6):1259–66.CrossRef
34.
go back to reference Mason JC. Takayasu arteritis–advances in diagnosis and management. Nat Rev Rheumatol. 2010;6(7):406–15.CrossRef Mason JC. Takayasu arteritis–advances in diagnosis and management. Nat Rev Rheumatol. 2010;6(7):406–15.CrossRef
35.
go back to reference Balink H, Bennink RJ, van Eck-Smit BL, et al. The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int. 2014;2014: 687608.CrossRef Balink H, Bennink RJ, van Eck-Smit BL, et al. The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int. 2014;2014: 687608.CrossRef
36.
go back to reference James OG, Christensen JD, Wong TZ, et al. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics. 2011;31(5):1271–86.CrossRef James OG, Christensen JD, Wong TZ, et al. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics. 2011;31(5):1271–86.CrossRef
37.
go back to reference Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41(2):300–15.CrossRef Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41(2):300–15.CrossRef
38.
go back to reference Stümer J, Biermann MHC, Knopf J, et al. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. Clin Exp Immunol. 2017;189(3):372–82.CrossRef Stümer J, Biermann MHC, Knopf J, et al. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. Clin Exp Immunol. 2017;189(3):372–82.CrossRef
39.
go back to reference Plomp R, Dekkers G, Rombouts Y, et al. Hinge-region O-glycosylation of human immunoglobulin G3 (IgG3). Mol Cell Proteomics. 2015;14(5):1373–84.CrossRef Plomp R, Dekkers G, Rombouts Y, et al. Hinge-region O-glycosylation of human immunoglobulin G3 (IgG3). Mol Cell Proteomics. 2015;14(5):1373–84.CrossRef
40.
go back to reference Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949–59.CrossRef Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949–59.CrossRef
41.
go back to reference Kanda Y, Yamada T, Mori K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104–18.CrossRef Kanda Y, Yamada T, Mori K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104–18.CrossRef
42.
go back to reference Zhou Q, Shankara S, Roy A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99(3):652–65.CrossRef Zhou Q, Shankara S, Roy A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99(3):652–65.CrossRef
43.
go back to reference Tripathy NK, Upadhyaya S, Sinha N, et al. Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu’s arteritis. J Rheumatol. 2001;28(4):805–8. Tripathy NK, Upadhyaya S, Sinha N, et al. Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu’s arteritis. J Rheumatol. 2001;28(4):805–8.
44.
go back to reference Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum. 2006;54(7):2326–33.CrossRef Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum. 2006;54(7):2326–33.CrossRef
Metadata
Title
Altered glycosylation profiles of serum IgG in Takayasu arteritis
Authors
Lingyu Liu
Jing Li
Yunjiao Yang
Chaojun Hu
Xinping Tian
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01035-4

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue